Empowered Patient Podcast

Dr. Nerissa Kreher, Chief Medical Officer, Tiburio discusses the company's lead asset, TBR-760 as a novel treatment option for patients with non-functioning pituitary adenomas (NFPA), which are rare neuroendocrine tumors located in the pituitary gland.  She also speaks about the challenges facing patients even after surgical or radiation treatments for these pituitary tumors. @TiburioT #neuroendocrine  #pituitaryadenoma  #chiefmedicalofficer  #raredisease  #NFPA  Tiburio Therapeutics Download the PDF file of the interview here.

Venkat Nelabhotla, Chief Executive Officer, Vyome Therapeutics discusses the growing problem of antimicrobial resistance in medicine and how Vyome is working to tackle resistant dermatological conditions using their understanding of the skin microbiome.  Focusing first on acne, Vyome is developing VB-1953, a topical gel capable of killing resistant strains of P. acnes to help deliver solutions to the more than 10 million patients in the US, and more world-wide, with antibiotic resistant acne. @vyometx Vyome Therapeutics

Dr. Greg van Wyk, CMO and recently appointed CEO, Noxopharm talks about the Company's current milestones and upcoming news related to its lead clinical drug candidate, Veyonda, a chemotherapy and radiation enhancer that is being studied in men with late stage metastatic prostate cancer and that may have broad applicability in other cancer types.  Greg notes the explosion of mergers and acquisitions particularly in the oncology space due to increasing interest in combining one or more molecules in treatments. @Noxopharm #prostatecancer  #cancer  #chemotherapy  #radiation Noxopharm

Terri Wingham, Founder, A Fresh Chapter was diagnosed with an aggressive form of cancer when she was in her 30's.  As a result she founded A Fresh Chapter, giving cancer survivors and caregivers an opportunity to travel to foreign and US destinations to get outside of their comfort zone and discover new possibilities, community and purpose.  These odysseys are supplemented by online resources and financial underwriting from corporate sponsors including Eli Lilly. @afreshchapter #cancer A Fresh Chapter

Preston Klassen, MD Chief Medical Officer, Arena Pharmaceuticals talks about the challenges of treating Inflammatory Bowel Diseases (IBD) and Arena's developmental therapies for ulcerative colitis and Crohn's disease.  We also talk about the development of a treatment for related gastrointestinal pain with a non-opioid alternative. #Arena  #Ulcerativecolitis #GI  #IBD  #crohns @ArenaPharm  Arena Pharmaceuticals     Arena Pharmaceuticals

Dr. Jean-Marc Steens, Chief Medical Officer, Abivax reports on clinical results that continue to show advances in the chronic treatment and maintenance of moderate to severe ulcerative colitis using a new small molecule ABX464 in an oral treatment and potential applications for other inflammatory and neurological diseases.  Jean-Marc also explains how another molecule ABX196 is being tested to determine if it might increase the outcome of treatments for hepatocellular carcinoma, the most common liver cancer, in conjunction with Opdivo a checkpoint inhibitor that is being developed with Scripps Research, University of Chicago and BYU.  #ulcerativecolitis Abivax    

Bob Anderson PhD, Chief Scientific Officer, ImmusanT is an internationally recognized leader in celiac disease research.  He talks about the underlying causes of celiac, who is most likely to have an acquired immune response to fragments of the gluten protein, educating doctors about the need to test for celiac, the Phase 2 clinical trial results for Nexvax2 a therapeutic vaccine to treat celiac, and how the ImmusanT platform technology is allowing development of therapeutic vaccines for diabetes and other autoimmune conditions. @ImmusanT #celiac  #celiacdisease #diabetes  #autoimmunediseases #tcell  #glutenpeptides  #peptides  #gluten  #immunology ImmusanT 

Amit Etkin MD PhD is a professor of psychiatry and behavioral sciences at the Stanford School of Medicine and expert in the neural basis of emotional disorders.  He talks about a recent study published in Science Translational Medicine, of which he was the lead author physician, on his research that lead to the discovery of the first imaging biomaker for PTSD.  Using fMRI and TMS with EEG, Amit was able to identify which patients were most likely to be helped by different treatment plans for post-traumatic stress disorder.  This research was funded in part by Cohen Veterans Bioscience, a translational research organization dedicated to fast-tracking personalized diagnostics and therapeutics for brain health. Cohen Veterans Bioscience

Dr. Vimal Mehta, CEO and Founder, BioXcel Therapeutics talks about using artificial intelligence approaches in the development of drugs.  BioXcel's two most advanced clinical development programs are (1) BXCL501, a sublingual thin film formulation designed for acute treatment of agitation resulting from neurological and psychiatric disorders like schizophrenia, bipolar disorder, Alzheimer's and opioid addiction and (2) BXCL701, an immuno-oncology agent designed for the treatment of a rare form of prostate cancer and for treatment of pancreatic cancer. BioXCel Therapeutics  

Marina Baroff, Senior Director, Service Innovation at Steps Through OC shines a light on the need to provide physical as well as emotional support to women living with ovarian cancer and their caregivers.  Marina talks about this new program of The Clearity Foundation with seed funding provided by the Susan Poorman Blackie Ovarian Cancer Foundation that matches patients and their caregivers with a professional ovarian cancer counselor at no charge.  This is not a support group but rather online, personalized treatment plans based on science and tailored to each person's unique situation. @stepsthrough @clearityfnd StepsThrough.org ClearityFoundation.org

Dr. Jay Venkatesan, CEO, Angion, a clinical stage biopharmaceutical company, discusses the company's work in organ self-repair and their initial focus in the nephrology space.  The company's lead candidate ANG-3777 is a small molecule that mimics a protein to stimulate this self-repair and regeneration following injury. Angion's therapeutic programs modulate the natural repair pathways of the body to fill unmet medical needs across many indications, including acute kidney injury, kidney transplantation, and chronic kidney disease. #organinjury  #organtransplant  #acutekidneyinjury #chronickidneydisease Angion

William Annett, CEO, OncoCyte discusses the exciting work the company is doing in the liquid biopsy space.  They have developed DetermaVu™ a liquid biopsy test for lung cancer, which studies show has the potential to detect the absence of cancer by analyzing a simple blood sample.  This technique allows individuals to potentially avoid risky, expensive lung biopsies.  The company recently announced promising R&D validation data and is planning to make the test available to patients and physicians later this year. @OncocyteLbx #LiquidBiopsy  #LungCancer #DetermaVu OncoCyte.com

Dr. Hartmut Ehrlich, CEO of Abivax discusses the exciting new progress that this French biotechnology company has observed in clinical trials of their most advanced clinical drug candidate, ABX464.  Originally designed to treat HIV by reducing the viral reservoir, Abivax determined the molecule could also be a game-changing treatment in a variety of inflammatory conditions like ulcerative colitis, Crohn's disease and arthritis. #Abivax #ABVX #HIV #UlcerativeColitis #UC #inflammation #IBD Abivax.com

Anna Landre is a Georgetown University sophomore who has a rare disease, spinal muscular atrophy (SMA) and is a wheelchair user.  In addition to being a full time student, Anna serves as Commissioner of the Advisory Neighborhood Commission where she advocates for people with disabilities and to improve accessibility on the Georgetown campus and in the district.  She talks about educating elected officials about possible ways to overcome challenges for those in wheelchairs and raising awareness about those living with rare diseases. #onestepaway  #SMA  #cureSMA  

Graham Kelly, CEO, Noxopharm discusses the company's lead clinical asset, Veyonda, a first-in-class chemotherapy and radiation enhancer that has immuno-oncology properties.  Veyonda has potential utility across solid tumors and boosts the effect of radiation therapy 2-3x in cancer cells.  It has already shown positive results in patients with metastatic castrate-resistant prostate cancer. #oncology #prostatecancer  #radiation #chemotherapy @Noxopharm Noxopharm

Jani Tuomi, Co-Founder, imaware and Kelly O'Neill, author and rheumatoid arthritis warrior talk about how at-home blood testing can empower patients with vital information to inform their discussions with doctors.  Both talk about how easy self testing for rheumatoid arthritis is a smart way to follow up on early warning signs of this often undiagnosed disease.   #rheumatoidarthritis @imaware_health @rawarrior imaware.health Rheumatoid Arthritis Unmasked: 10 Dangers of Rheumatoid Disease

Frank Ochberg MD is a psychiatrist, pioneer in trauma science, and co-founder of the Trust for Trauma Journalism, an organization with the goal of providing funding to advance exemplary reporting and the care of journalists who are bearing witness to violence, conflict and tragedy.  We talk about journalists as first responders, recognizing and treating their PTSD, and how all of us process trauma. #PTSD Trust for Trauma Journalism

Dr. Dan Alkon, President and Chief Scientific Officer, Neurotrope is an internationally recognized pioneer in research on brain based neural networks, the molecular basis of memory and degenerative brain disorders.  Neurotrope has seen very promising results in clinical trials with Bryostatin-1 with patients with advanced Alzheimer's disease, in many cases reversing the damage done to synapses and improving memory. They are on the path to attacking the progression of Alzheimer's and not just treating the symptoms. #neurotrope  #alzheimersdisease  #alzheimers #biotechnology  #biotech  #pharma @Neurotrope1 Neurotrope.com

Bob Geho, CEO, Diasome discusses the current treatments for diabetes and the nearly 100 year history of insulin.  He talks about the company's hepatocyte directed vesicle (HDV) nanotechnology that can be added to any insulin to lessen the instances of high and low blood sugar levels in people with diabetes.  HDV nanotechnology can be added to any insulin to improve its safety and efficacy by targeting specific organs and in this case, restoring the liver's natural role in blood glucose control. #Type1Diabetes  #Type2Diabetes  #Diabetes #Insulin @diasome Diasome.com

Brad Younggren MD, Chief Medical Officer, 98point was trained as an emergency medicine doctor and has brought his expertise to the online world of on-demand primary care.  Brad talks about the value of giving patients access to accurate resources at any time of the day to diagnose symptoms, recommend treatment, escalate to other medical professionals, and help manage chronic conditions.  Using a mobile app and artificial intelligence along with real primary care doctors, 98point is encouraging patients of all ages to take more direct control of their own health. @98point6inc 98Point6.com